Bharat Biotech’s nasal vaccine gets approval for Phase II and III clinical trials

Nasal Vaccine: The first nasal (nasal spray) vaccine developed by Bharat Biotech against Covid-19 has been approved for Phase II and III pilot trials. The Department of Biotechnology has given this information. The first phase trial has been done on people between the ages of 18 and 60, the statement said.

Let us inform that at present, three vaccines are available in the country for the common people, Bharat Biotech’s Covaxin, Serum Institute’s Covishield and Russia’s Sputnik V. The government has also approved Moderna’s mRNA vaccine and Johnson & Johnson’s single dose vaccine for use.

So far 52.95 crore doses of anti-corona vaccine have been given in the country. According to the Ministry of Health, on Thursday, 27,83,649 people in the age group of 18 to 44 years were given the first dose and 4,85,193 were given the second dose.

Source link

- Advertisement -